isco.ob - a new approach to developing stem cell therapy

8/4/2019 ISCO.OB - A New Approach to Developing Stem Cell Therapy

1/17

1

(ISCO.OB)

A New Approach to DevelopingStem Cell Therapy


2/17

Statements pertaining to anticipated technological developments andtherapeutic applications, the potential benefits of collaborations,affiliations, and other opportunities for the company and its subsidiaries,along with other statements about the future expectations, beliefs, goals,plans, or prospects expressed by management constitute forward-lookingstatements. Any statements that are not historical fact (including, but notlimited to statements that contain words such as "will," "should,"

"believes," "plans," "anticipates," "expects," "estimates,") should also beconsidered to be forward-looking statements. Forward-looking statementsinvolve risks and uncertainties, including, without limitation, risks inherentin the development and/or commercialization of potential products,uncertainty in the results of clinical trials or regulatory approvals, need andability to obtain future capital, application of capital resources among

competing uses, and maintenance of intellectual property rights. Actualresults may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with themany uncertainties that affect the company's business, particularly thosementioned in the cautionary statements found in the company's Securitiesand Exchange Commission filings. The company disclaims any intent orobligation to update these forward-looking statements.

2

Forward-looking statements


3/17

ISCO.OB

3

Common shares outstanding: 76 million

Public float: 69.4 million

Share price (recent): 0.94 (12 months: $0.67 - $2.37)

Market capitalization: ~$72 million

2010 revenue: $1.6 million

Q-2 2011 revenue $ 1.1 million

$25 million equity capital committed if needed


4/17

Our Goal: Build a Billion DollarCompany

4

1. Control The IP

2. Pick Big Markets

3. Create a Revenue Base

4. Build the Right Team

5. Put it All Together


5/17

The IP

5

1. Parthenogenesis: a Unique Technology

2. We Own It

3. Changes the Whole Business Model


6/17

6

Why Parthenogenesis Matters

hpSCs Embryonic iPS Adult SCsEthics(Relative to destruction ofviable human embryos)

No viableembryo

Destroysviable embryo

No embryo No embryo

Immune matchingand cell banking(practical source of cells)

Matchesmillions ofpatients

Matchesdonor only.

Matchesdonor only

Matchesdonor only

Pluripotency(Become cells from all partsof body)

Yes Yes Yes No

Proliferation(Ease of expansion inculture)

Strong Strong Strong Weak

Genetic

Manipulation(Restructuring of geneexpression patterns)

Minimal Minimal Substantial Minimal

Application forDiseases withGeneticComponent

Superior SuperiorDeficient

(carry damagedgene)

Deficient(carry damaged

gene)


7/177

Big Markets

Cornea: Pre-clinical trials

10 million corneal blindness cases worldwide

Toxicity testing: $1billion secondary market

Retina: Pre-clinical trials

AMD: 1.75 million US Patients

Retinitis pigmentosa (RP): 100,000 US Patients

Liver: Successful pre-clinical engraftment; newway to create pure cell population discovered

30,000 deaths/year in the US

15,750 on transplant waiting list

Neurological Diseases: Pre-clinical trials

Parkinsons, Alzheimers, etc)

Each a huge Market


8/17

Universal Stem Cell Banking

Every person has an immune type

There are 200 common types in a typical populationParthenogenetic stem cells: Can be matched to millions of people Example: 5 cell lines could match 42 million in the USA

A Bank of these could provide immune-matched cellsfor millions at a cost they could afford

For the Scientist


9/17

Revenue Sources

9

1. Skin Care

2. Research Products

3. Embedded Technology


10/17

Development Built from ISCO Cells Clinically tested for safety and efficacy

Commercialization

Direct-to-consumer; physicians and spas $1.1 million sales in first launch Could solve cash flow issues for whole Company

10

Baseline 6 weeks 16 weeks

Lifeline Skin Care


11/17

Biomedical Products

>130 products: growth factors, media and human cells More new products in 2009-10 than the market-leader cGMP media and cell manufacturing capacity

Distribution

Direct sales (USA) International distributors: Europe, Asia (incl.India)

OEM partners: ATCC, Millipore, Life Technologies

11


12/17

Thread-based vascular graft(off the shelf, allogeneic)

Addressable market: 500,000 patients

Revenue > $100 Million/year

Embedded Technology--Example

Confidenti


13/17

Executive Team

Kenneth Aldrich, Esq., Executive Chairman

30 years investment in and management of public and private companiesAndrey Semechkin, Ph.D., CEO

Member of Russian Academy of Sciences Successful founder and manager of international companies

Jeffrey Janus, SVP and CEO Lifeline Cell Technology

25 years experience with cell-based and FDA-compliant biological products Founder of Clonetics (now research product market leader Lonza)

Ruslan Semechkin, Ph.D., VP and CEO Lifeline Skin Care

Medical science and cosmeceutical development experience

Kurt May, Sr. VP GTE, Price Smart, Psynomics, University of San Diego

Simon Craw, Ph.D., VP

Executive with Merck, AstraZeneca and Novartis 22 years scientific operational experience

13


14/17

Putting It All Together

14

Parthenogenetic

Stem Cells

LifelineBioresearch

Products

Stem Cell Bank

LifelineSkin Care

Products

Therapeutic

Development

Partnering


15/17

Investment Highlights

15

Better than embryonic stem cellsPatented

Technology Proven

Stem Cell Bank

Manufacturing capacity and know-how in place

Cash flow today

Viable international business model


16/17

Whats Next for 2012?

16

1. Continued Expansion Stem Cell Bank

2. First Customers for Toxicity Testing

3. Increased Skin Care Sales

4. Increased Sales in Lifeline CellTechnology

5. New Scientific Findings6. Possible Start of Clinical Trials

a. Liverb. Cornea

c. Retina


17/1717

Contact information

www.internationalstemcell.com

Kenneth Aldrich, Chairman760-940-6383

[email protected]
mailto:[email protected]:[email protected]

isco.ob - a new approach to developing stem cell therapy

Documents